RE:RE:RE:RE:RE:RE:FDA in <2weeks?I don't think the Trogarzo IM data matters much to the stock price whether it is good or bad. I am not sure about the timing of the Egrifta human factor study (when will the FDA approve of it assuming it is good info?) but as long as it is good, I don't think it has any notable impact on the stock. If it was somehow bad, which seems very unlikely, that would be quite bad for THTX. The FDA nod to restart the TH-1902 trial and the investor call should have some positive effet on the share price, but I am not thinkingit will be huge. The stock needs good TH-1902 data to really get moving - maybe the presentation of phase 1A data will have some real encouragement in it but I still don't think the market will give it much credence until positive phase 1b data is available.
The board started losing shareholder support with the first OO. Given the recent vote, it would seem suicidal for them to do another.
Trogarzon wrote: Well we are due for Trogarzo IM data, Egrifta Human Factor validation, and FDA go on TH1902 and following pow wow. And my personnal guess another OO with canadian brokers.